emtricitabine has been researched along with gsk1265744 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 15 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Harris, P; Henderson, R | 1 |
| Adeyeye, A; Agyei, Y; Anderson, PL; Bushman, LR; Chau, G; Cohen, MS; Cummings, V; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Fogel, JM; Ford, S; Haines, CD; Hanscom, B; Hendrix, CW; Hosseinipour, M; Hughes, JP; Hunidzarira, P; Kofron, R; Marzinke, MA; Mathew, CA; Mellors, J; Mpendo, J; Nair, G; Persaud, D; Petropoulos, C; Piwowar-Manning, E; Richardson, P; Rinehart, A; Rooney, JF; Spooner, E; St Clair, M; Sullivan, P | 1 |
| Adeyeye, A; Anderson, PL; Beigel-Orme, S; Bock, P; Cohen, MS; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Hanscom, B; Hendrix, CW; Hosek, S; Hosseinipour, MC; Hughes, JP; Hunidzarira, P; Kalonji, D; Kayange, N; Makhema, J; Mandima, P; Marzinke, MA; Mathew, C; Mgodi, N; Mpendo, J; Mukwekwerere, P; Nair, G; Nakabiito, C; Ntege, PN; Nuwagaba-Biribonwoha, H; Ouma, SG; Panchia, R; Rinehart, A; Rooney, JF; Rose, S; Singh, N; Sista, N; Siziba, B; Smith, K; Spooner, E; Spreen, WR; Tolley, E | 1 |
| Joob, B; Wiwanikit, V | 1 |
| Chahine, EB; Durham, SH; Milam, A; Waer, D | 1 |
| Blair, HA | 1 |
| Delany-Moretlwe, S; Hosseinipour, MC; Jamieson, L; Johnson, LF; Meyer-Rath, G; Nichols, BE; Russell, C | 1 |
| Adeyeye, A; Anderson, PL; Arduino, RC; Bhandari, P; Bushman, LR; Chariyalertsak, S; Cohen, MS; Eshleman, SH; Fogel, JM; Ford, SL; Gollings, R; Grinsztejn, B; Halvas, EK; Hanscom, B; Hendrix, CW; Kofron, R; Landovitz, RJ; Marzinke, MA; Mayer, K; McCauley, M; Mellors, J; Moser, A; Persaud, D; Piwowar-Manning, E; Rinehart, AR; Rooney, JF; St Clair, M; Wang, Z; Weng, L | 1 |
| Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X | 1 |
| Baeten, JM; Bekker, LG; Cohen, MS; Corey, L; Delany-Moretlwe, S; Donnell, D; Edupuganti, S; Gao, F; Gray, G; Hanscom, B; Hosseinipour, M; Hughes, JP; Mgodi, N; Rees, H | 1 |
| Barnabas, R; Boily, MC; Dimitrov, DT; Donnell, DJ; Doyle, CM; Hanscom, B; Heitner, J; Maheu-Giroux, M; Milwid, RM; Mitchell, KM; Moore, M; Stansfield, SE; Vijver, DV; Wang, H; Xia, Y | 1 |
| Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F | 1 |
| Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z | 1 |
| Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV | 1 |
3 review(s) available for emtricitabine and gsk1265744
| Article | Year |
|---|---|
Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2023 |
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2022 |
Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Topics: Anti-HIV Agents; Creatinine; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
5 trial(s) available for emtricitabine and gsk1265744
| Article | Year |
|---|---|
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Topics: Anti-HIV Agents; Diketopiperazines; DNA-Directed RNA Polymerases; Emtricitabine; Female; HIV; HIV Infections; Humans; Nucleosides; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Topics: Adult; Anti-HIV Agents; Child; Diketopiperazines; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Pregnancy; Pyridones | 2022 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult | 2023 |
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Hormones; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Thailand; Transgender Persons | 2023 |
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
7 other study(ies) available for emtricitabine and gsk1265744
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Highlights of HIVR4P // Virtual.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual Behavior; Tenofovir | 2021 |
Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Diketopiperazines; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2022 |
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Topics: Adenine; Adolescent; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sex Workers; Sexual and Gender Minorities; South Africa; Tenofovir | 2022 |
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2023 |
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Topics: Black People; Canada; Emtricitabine; Georgia; HIV Infections; Homosexuality, Male; Humans; Male; Netherlands; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; White | 2023 |